natgillin/translations-raw huggingface dataset:
R10, at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kada je prisutan, je nezavisno izabran između alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, pri čemu cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, gdje heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
A compound for use according to Claim 1 wherein: 
Spoj za uporabu, prema zahtjevu 1, gdje:
The compound for use of Claim 1 comprising the use of an additional therapeutic agent. 
Spoj za uporabu, prema zahtjevu 1, obuhvaća i uporabu dodatnog terapijskog sredstva.
The compound for use of Claim 16 wherein the additional therapeutic agent is a dipeptidyl peptidase-IV (DPP4) inhibitor. 
Spoj za uporabu, prema zahtjevu 16, gdje dodatno terapijsko sredstvo inhibitor dipeptidil peptidaze-IV (DPP4).
A compound of Claim 19 and, optionally, an additional therapeutic agent for use in a method of modulating the activity of the GPR11 G-protein-coupled receptor comprising administering to a mammalian patient in need a therapetically effective amount of the above compound. 
Spoj prema zahtjevu 19 i, izborno, dodatno terapijsko sredstvo za uporabu u postupku modulacije aktivnosti GPR11 G-protein-vezanog receptora, postupak obuhvaća davanje učinkovite količine gornjjeg spoja, bolesniku sisavcu kod kojeg postoji potreba.
and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1. 
gdje kada R1 je klor, a p je 1, takav R1 se ne nalazi u orto položaju u odnosu na vezu koja ga povezuje s ostatkom molekule; te gdje kada R1 odgovara R5, p je 1.
The sterile liquid formulation of claim 7 wherein each 0.5 mL dose is formulated to contain: 2 µg of each saccharide, except for 6B at 4 µg; approximately 29 µg CRM197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients. 
Sterilna tekuća formulacija u skladu s patentnim zahtjevom 7, naznačena time što je svaka doza od 0,5 ml tako formulirana da sadrži: 2 µg svakog saharida, izuzev 6B (4 µg); otprilike 29 µg proteina CRM197 kao nosača; adjuvans s 0,125 mg elementarnog aluminija (0,5 mg aluminijevog fosfata); te pufer od natrijevog klorida i natrijevog sukcinata, kao pomoćne tvari.
The process according to claim 11 wherein the additional isolation of the other diastereoisomeric salt of formula (II) comprises the concentration of the mother liquor generated upon isolating the first diastereoisomeric salt and subsequent crystallization to obtain said other diastereoismeric salt. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se dodatno izdvajanje druge dijastereoizomerne soli formule (II) sastoji u koncentriranju matičnog luga dobivenog prilikom izdvajanja prve dijastereoizomerne soli i kristalizacije nakon toga kako bi se dobilo navedenu drugu dijastereoizomernu sol.
A Cladribine-free period wherein no Cladribine is administered. 
period bez kladribina, kada se ne primjenjuje kladribin.
A Cladribine-free period wherein no Cladribine is administered; 
period bez kladribina, kada se ne primijenjuje kladribin;
Use according to any of the preceding claims wherein the total dose of Cladribine reached at the end of the induction period is 3.5 mg/kg and the total dose of Cladribine reached at the end of the maintenance period is 1.7 mg/kg. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je ukupna doza kladribina postignuta na kraju perioda uvođenja otprilike 3,5 mg/kg, a ukupna doza kladribina postignuta na kraju perioda održavanja je otprilike 1,7 mg/kg.
Use according to any of the preceding claims wherein the pharmaceutical formulation is to be orally administered at a daily dose of Cladribine 3 to 30 mg Cladribine. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti oralno, u dnevnoj dozi od 3 do 30 mg kladribina.
Use according to any of the preceding claims wherein the pharmaceutical formulation is to be orally administered at a daily dose of Cladribine 10 mg Cladribine. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti oralno, u dnevnoj dozi od 10 mg kladribina.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound cyprodinil. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound chlorothalonil. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound bixafen. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
Use of a compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of IGF-IR or ALK. The use according to claim 6, wherein the disease to be treated is selected from proliferative disease. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti koje odgovaraju na inhibiciju od FAK i/ili ALK i/ili ZAP-70 i/ili JGF-IR, pri čemu se bolest koja se treba liječiti odabire od proliferativnih bolesti.
as active ingredients, a combination of admixed or separately packaged: 
– kao aktivne sastojke, kombinaciju pomiješanih ili odvojeno pakiranih:
pantothenic acid; and the following optional components: 
pantotenska kiselina; i – slijedeće izborne komponente:
an amino acid selected from the group consisting of valine, leucine, isoleucine or mixtures thereof; 
aminokiselina, koju se bira iz skupine koju čine valin, leucin, izoleucin ili njihove smjese;
a creatine selected from the group consisting of creatine and phosphocreatine or mixtures thereof; and 
kreatin, kojeg se bira iz skupine koju čine kreatin i fosfokreatin ili njihove smjese; i
a mineral salt. 
mineralna sol.
The dietary supplement of claim 1 wherein the pharmacologically acceptable salt is selected from the group consisting of: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; tartrate; trichloroacetate; trifluoroacetate and methane sulphonate. 
Dodatak prehrani u skladu s patentnim zahtjevom 1, naznačen time što se farmakološki prihvatljivu sol bira iz skupine koju čine: klorid; bromid; jodid; aspartat, kiseli aspartat; citrat, kiseli citrat; fosfat, kiseli fosfat; fumarat, kiseli fumarat; glicerofosfat; glukozni fosfat; laktat; maleat, kiseli maleat; mukat; orotat; oksalat; kiseli oksalat; sulfat, kiseli sulfat; tartarat; trikloracetat; trifluoracetat i metansulfonat.
The dietary supplement of claim 1 wherein the weight ratio (a):(b):(c):(d) ranges from 10:0.04:0.08:0.4 to 1:4:4:20. 
Dodatak prehrani u skladu s patentnim zahtjevom 1, naznačen time što se težinski omjer (a):(b):(c):(d) kreće od 10:0,04:0,08:0,4 to 1:4:4:20.
The dietary supplement of claim 4 wherein the weight ratio (a):(b):(c):(d) ranges from 10:2:2:2 to 1:1:1:5. 
Dodatak prehrani u skladu s patentnim zahtjevom 4, naznačen time što se težinski omjer (a):(b):(c):(d) kreće od 10:2:2:2 do 1:1:1:5.
The dietary supplement of claim 1 in the form of tablets, lozenges, pills, capsules and granulates. 
Dodatak prehrani u skladu s patentnim zahtjevom 1, naznačen time što je u obliku tableta, lozengeta, pilula, kapsula i granulata.
A method of providing energy and strengthening skeletal muscle comprising administering a dietary supplement according to anyone of claims 1 to 7. 
Postupak osiguravanja energije i jačanja skeletnih mišića, naznačen time što se sastoji u primjeni dodatka prehrani u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
A sunflower plant comprising in its genome at least one copy of at least one endogenous gene comprising an acetohydroxyacid synthase large subunit (AHASL) polynucleotide, wherein said AHASL polynucleotide encodes an imidazolinone herbicide-resistant AHASL1 protein comprising the amino acid sequence set forth in SEQ ID NO:2, or progeny sunflower plant thereof, and wherein said plant, or progeny thereof, has increased resistance to at least one imidazolinone herbicide as compared to a wild-type sunflower plant. 
Biljka suncokreta, naznačena time, da u svojem genomu sadrži barem jednu kopiju od barem jednog endogenog gena koji sadrži veliku podjedinicu polinukleotida sinteze acetohidroksilne kiseline (AHASL), gdje spomenuti AHASL polinukleotid kodira imidazolinon AHASL1 protein otporan na herbicide, koji sadrži sekvencu amino kiseline iznesenu u SEQ ID NO:2; ili njezina biljka potomak, pri čemu spomenuta biljka suncokreta ili njezin potomak, ima povećanu otpornost na barem jedan imidazolinonski herbicid u usporedbi s divljim tipom biljke suncokreta.
The sunflower plant of claim 1 or 2, wherein said herbicide-resistant AHASL polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 1. 
Biljka suncokreta prema zahtjevu 1 ili 2, naznačena time, da spomenuti AHASL polinukleotid otporan na herbicide sadrži sekvencu nukleotida iznesenu u SEQ ID NO:1.
A sunflower plant according to any one of claims 1 to 5 comprising the imidazolinone herbicide-resistance characteristics of line GM40 or GM1606, a sample of seed of the line having been respectively deposited with the ATCC Patent Deposit Number PTA-6716 or the ATCC Patent Deposit Number PTA-7606, wherein said plant: 
Biljka suncokreta prema bilo kojem od zahtjeva 1 do 5, naznačena time, da obuhvaća svojstva imidazolinona otpornog na herbicide linije GM40 ili GM1606, uzorak sjemena linije koja je bila deponirana pri ATCC Patent Deposit Number PTA-6716 odnosno pri ATCC Patent Deposit Number PTA-7606, pri čemu je biljka:
compound 50 A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 4. 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljive nosače i kao aktivni sastojak terapeutski učinkovitu količinu spoja prema zahtjevu 1 do 4.
reacting an intermediate of formula (II), wherein Q is C1-2alkyloxycarbonyl, herein referred to as intermediates of formula (II-c), with hydroxylamine, in the presence of a base and in an appropriate solvent with the production of a hydroxamic acid of formula (I) 
reakciju intermedijera formule (II), pri čemu Q je C1-2alkiloksikarbonil, ovdje se naziva kao intermedijeri formule (II-c), sa hidroksilaminom, u prisutnosti baze i u odgovarajućem otapalu uz dobivanje hidroksamske kiseline sa formulom (I) [image]
reacting an intermediate of formula (VI) with the appropriate carboxaldehyde of formula (V), wherein t is an integer with value 0 or 1, and when t is 0 then a direct bond is intended, in the presence of an appropriate reagent, with the formation of a compound of formula (II-a), 
reakciju intermedijera formule (VI) sa odgovarajućim karboksaldehidom formule (V), pri čemu t je cijeli broj sa vrijednosti 0 ili 1, te kada t je 0 tada je namjeravana direktna veza, u prisutnosti odgovarajućeg reagensa, uz formiranje spoja formule (II-a), [image]
reacting the carboxylic acid ethyl ester of formula (IV) with the appropriate carboxaldehyde of formula (V), in the presence of an appropriate reagent, with the formation of a compound of formula (II-c), 
reakciju etil estera karboksilne kiseline formule (IV) sa odgovarajućim karboksaldehidom formule (V), u prisutnosti odgovarajućeg reagensa, uz formiranje spoja formule (II-c), [image]
reacting an intermediate od formula (XIV) with the appropriate intermediate of formula (XV), in the presence of an appropriate reagent, in a suitable solvent, with the formation of a compound of formula (II-c), 
reakciju intermedijera formule (XIV) sa odgovarajućim intermedijerom formule (XV), u prisutnosti odgovarajućeg reagensa, u pogodnom otapalu, uz formiranje spoja formule (II-c), [image]
reacting an intermediate of formula (X) with an intermediate of formula (XI) wherein W is an appropriate leaving group such as, for example, halo, e.g. 
reakciju intermedijera formule (X) sa intermedijerom formule (XI) pri čemu W je odgovarajuća odlazna skupina kao, na primjer, halo, npr.
reacting an intermediate of formula (XII) with an intermediate of formula (XIII), wherein W is an appropriate leaving group as described above, with the formation of a compound of formula (II-c). 
reakciju intermedijera formule (XII) sa intermedijerom formule (XIII), pri čemu W je odgovarajuća odlazna skupina kako je gore opisano, uz formiranje spoja formule (II-c). [image]
an HDAC inhibitor, wherein the HDAC inhibitor is a compound of the following formula or pharmaceutically acceptable salt or solvate thereof: and arginine. 
HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom, ili njegov(a) farmaceutski prihvatljiva sol ili solvat: [image] i arginin.
A pharmaceutical composition according to claim 1, comprising: 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da sadrži:
an HDAC inhibitor, wherein the HDAC inhibitor is a compound of the following formula: and arginine. 
HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom: [image] i arginin.
A pharmaceutical composition according to claim 1 or 2, wherein said arginine is free arginine or a pharmaceutically acceptable salt of arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni arginin ili farmaceutski prihvatljiva sol od arginina.
A pharmaceutical composition according to claim 1 or 2, wherein said arginine is free arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni arginin.
A pharmaceutical composition according to claim 1 or 2, wherein said arginine is free L-arginine or a pharmaceutically acceptable salt of L-arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin ili farmaceutski prihvatljiva sol od L-arginina.
A pharmaceutical composition according to claim 1 or 2, wherein said arginine is free L-arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin.
A pharmaceutical composition according to any one of claims 1 to 6, wherein the molar ratio of arginine to said HDAC inhibitor is at least 0.5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5.
A pharmaceutical composition according to any one of claims 1 to 6, wherein the molar ratio of arginine to said HDAC inhibitor is from 0.5 to 5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5 do 5.
A pharmaceutical composition according to any one of claims 1 to 8, further comprising one or more additional pharmaceutically acceptable ingredients. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 8, naznačen time, da nadalje sadrži dodatne farmaceutski prihvatljive sastojke.
A pharmaceutical composition according to claim 11 or 12, further comprising: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution. 
Farmaceutski sastav prema zahtjevu 11 ili 12, naznačen time, da nadalje sadrži: vodu za injekciju, vodenu solnu otopinu, vodenu otopinu glukoze, vodenu otopinu soli za injekciju/infuziju, glukozu za injekciju/infuziju, Ringer-ovu otopinu, ili mliječnu Ringer-ovu otopinu.
A pharmaceutical composition according to claim 11 or 12, further comprising: aqueous saline solution or aqueous glucose solution. 
Farmaceutski sastav prema zahtjevu 11 ili 12, naznačen time, da nadalje sadrži: vodenu solnu otopinu ili vodenu otopinu glukoze.
A pharmaceutical composition according to any one of claims 11 to 26, wherein said composition is suitable for parenteral administration to a patient. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za parenteralnu primjenu na pacijentu.
A pharmaceutical composition according to any one of claims 11 to 26, wherein said composition is suitable for administration to a patient by injection. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću injekcije.
A pharmaceutical composition according to any one of claims 11 to 26, wherein said composition is suitable for administration to a patient by infusion. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću infuzije.
A pharmaceutical composition according to claim 1, wherein said HDAC inhibitor is: wherein said pharmaceutical composition is an aqueous liquid; 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da spomenuti HDAC inhibitor je: [image] pri čemu spomenuti farmaceutski sastav je vodena tekućina;
wherein said pharmaceutical composition comprises said HDAC inhibitor at a concentration of -50 mg/mL. 
dok spomenuti farmaceutski sastav sadrži spomenuti HDAC inhibitor u koncentraciji od -50 mg/mL.
A composition according to claim 30, wherein the molar ratio of said arginine to said HDAC inhibitor is from 0.8 to 4. 
Farmaceutski sastav prema zahtjevu 30, naznačen time, da je molarni odnos spomenutog arginina prema spomenutom HDAC inhibitoru od 0,8 do 4.
A pharmaceutical composition according to claim 1, consisting essentially of. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da se uglavnom sastoji od:
A composition according to claim 32, wherein said pharmaceutical composition comprises said HDAC inhibitor at a concentration of -50 mg/mL. 
Sastav prema zahtjevu 32, naznačen time, da spomenuti farmaceutski sastav sadrži HDAC inhibitor u koncentraciji od -50 mg/mL.
A composition according to claim 32 or 33, wherein the molar ratio of said L-arginine to said HDAC inhibitor is from 0.8 to 4. 
Sastav prema zahtjevu 32 ili 33, naznačen time, da je molarni odnos spomenutog L-arginina prema spomenutom HDAC inhibitoru od 0,8 do 4.
A pharmaceutical composition according to any one of claims 1 to 36, for use in a method of treatment of psoriasis. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 36, naznačen time, da je za uporabu u postupku liječenja psorijaze.
A pharmaceutical composition according to any one of claims 1 to 36, for use in a method of treatment of liver fibrosis, atherosclerosis, restenosis, Alzheimer's, Parkinson's, Huntington's chorea, amyotropic lateral sclerosis, spino-cerebellar degeneration, osteoarthritis, rheumatoid arthritis, diabetic retinopathy, anaemia, sickle cell anaemia, thalassaeimia, malaria, trypanosomiasis, helminthiasis, multiple sclerosis, autoimmune diabetes, lupus, atopic dermatitis, asthma, allergic rhinitis, or inflammatory bowel disease. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 36, naznačen time, da je za uporabu u postupku liječenja jetrene fibroze, ateroskleroze, restenoze, Alzheimer-ove bolesti, Parkinson-ove bolesti, Huntington-ove horeje, amiotropične lateralne skleroze, spino-cerebralne degeneracije, osteoartritisa, reumatoidnog artritisa, dijabetičke retinopatije, anemije, anemije srpastih stanica, talasemije, malarije, tripanosomijaze, helmintijaze, multiple skleroze, autoimunog dijabetesa, lupusa, atopičnog dermatitisa, astme, alergijskog rinitisa ili upalne bolesti crijeva.
an HDAC inhibitor, wherein the HDAC inhibitor is a compound of the following formula or pharmaceutically acceptable salt or solvate thereof: and 
HDAC inhibitora, pri čemu HDAC inhibitor je spoj sljedeće formule, ili njegov(a) farmaceutski prihvatljiva sol ili solvat: [image] i
in the manufacture of a medicament for the treatment of psoriasis. Use of: 
naznačena time, da je za proizvodnju lijeka za liječenje raka.